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MicroRNAs are small nonprotein-coding RNAs that regulate the expressions of a wide variety of genes by sequence-specific base
pairing on the 3′UTR of mRNA targets resulting in mRNA degradation or inhibition of translation. Aberrant expressions of
miRNAs have been linked to tumor development, metastasis, diagnosis, prognosis, and therapy response in human breast cancer.
Some miRNAs have been considered to have potential clinical applications as a tool for breast cancer prognosis and therapy.
Here we describe and discuss lines of evidence supporting the important relationship between miRNAs and breast cancer, and its
therapeutic strategies.
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1. Introduction
Recently, the discovery of a class of small nonprotein-
coding RNAs, so-called microRNAs (miRNAs), has opened
new opportunities in cancer biology. MiRNAs are 19–25-
nucleotides regulatory nonprotein-coding RNA molecules
that regulate the expressions of a wide variety of genes
by sequence-specific base pairing on the 3′ untranslated
regions (3′UTR) of the target mRNA resulting in mRNA
degradation or inhibition of translation. Patterns of miRNA
expression are meticulously regulated and play important
roles in oncogenesis [1, 2]. In the last decade, the number
of human genes known to be regulated by miRNAs is
growing rapidly [3, 4]. Increasing numbers of studies showed
that miRNA expression correlates with various cancers
and thought to function as both tumor suppressors and
oncogenes. Downregulation or accumulation of subsets of
miRNAs implies a tumor suppressor or oncogenic function,
respectively, is often seen in tumor development, as in the
examples of downregulated let-7 in lung cancer [5], deleted
or downregulated miR-15 and miR-16 in chronic lympho-
cytic leukemia [6], and miR-17-5p and miR-20a control the
balance of cell death and proliferation [7]. To date more than
700 human miRNAs are annotated in the miRBase registry
(miRBase version 12.0), but most of the genes regulated
by human miRNAs are not well defined. These miRNAs
are also predicted to regulate 30% protein-coding genes in
the human genome, indicating their importance as global
regulators in gene expression [8]. In this review, we will
focus on recent findings of miRNAs related to breast cancer
development and explore the potential usefulness of miRNAs
for the diagnosis, prognosis, and potential therapeutic targets
of breast cancer.
2. Aberrant Expression of miRNAs in
Human Breast Cancer
Over recent years, miRNA expression studies, especially
large-scale profiling, have been providing certain detailed
overview that aberrant expression of miRNAs is associated
with human breast cancer. By using high-density microarray
approaches, a set of significant deregulated miRNAs has
been revealed in breast tumors compared to normal breast
tissues [9–11]. Lu et al. [11] reported that miRNA expression
globally downregulated in tumors, including breast cancer,
compared to normal tissues, and demonstrated that miRNA
signature can classify human cancers according to develop-
mental lineage and differentiation status more accurate than
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mRNA expression profiles. The first report describing breast
cancer-specific miRNA profiling on a large set of tumor
and normal breast tissues identified a list of 29 differentially
expressed miRNAs and was able to discriminate tumors
from normal tissues with high accuracy [9]. Among the
differentially expressed miRNAs in breast cancer, miR-10b,
miR-125b, miR-145, miR-21, and miR-155 were revealed to
be the most consistently deregulated. The downregulation
of miR-10b, miR-125b, and miR-145 and upregulation of
miR-21 and miR-155 suggested that these miRNAs could
play a role as tumor suppressor genes or oncogenes. A
recent study used miRNA profiling to classify the subtypes of
breast tumors and identified a number of miRNAs associated
with molecular subtypes of breast cancer and some miRNAs
correlated with clinicopathological parameters [12]. Intrigu-
ingly, another recent report connected four miRNAs (miR-
7, miR-128a, miR-210, and miR-51-3p) to breast cancer
progression of Estrogen receptor (ER) positive and lymph
node negative [13].
3. Functional Effects of miRNAs and Targets
The involvement of miRNAs in cancer etiology is emerging
because of their capacity to directly target gene transcripts
and influence cellular physiology. Since miRNAs can expli-
cate their function via regulation of specific mRNAs, there
has been a great interest in identifying their targets.
Among the miRNAs identified as potential oncogene,
miR-21 is one of the best evaluated miRNAs. Overexpression
of miR-21 has been identified commonly in solid tumors
of the lung, breast, stomach, prostate, colon, brain, head
and neck, esophagus and pancreas [10, 14–16]. In breast
cancer, suppression of miR-21 both in vitro and in vivo led
to increase in apoptosis and downregulated the antiapoptotic
factor Bcl-2 [15]. Another potential gene targeted by miR-
21 in breast cancer was Tropomyosin 1 (TPM1), which
play an important role in antioncogenic function including
binding microfilaments and regulating cytoskeletonmiRNAs
[17]. Several potential target genes of miR-21 have been
identified including the tumor suppressor PTEN, and the
protein programmed cell death 4 (PDCD4) [18, 19]. These
findings suggest that miR-21 acts as an oncogene in breast
cancer development.
miR-10b is another miRNA that seems to play a vital role
in breast cancer. The expression of miR-10b was found to be
associated with clinical progression and metastasis in breast
carcinoma [20]. They reported that miR-10b is indeed down
modulated in all the breast carcinomas from metastasis-free
patients. Nevertheless, half of the patients with metastasis
showed elevated miR-10b levels in their primary tumors.
This study also revealed that miR-10b regulated homeobox
D10, leading to upregulation of the prometastatic gene
RHOC and thus result in cell invasion and metastasis.
miR-27a is reported to target the transcription factor
ZBTB10/RINZF, which is a putative suppressor of speci-
ficity protein (Sp) [21]. Overexpression of Sp by miR-27a
contributes to the increased expression of Sp-dependent
survival and angiogenic genes, including survivin, vascular
endothelial growth factor (VEGF), and VEGF receptor 1
(VEGFR1). Thus, the oncogenic activity of miR-27a in breast
cancer cells is due, in part, to suppression of ZBTB10.
Another crucial pathway in breast cancer is estrogen
mediated signaling. In one study, it is reported that miR-
206 expression is significantly downregulated in estrogen
receptor alpha (ERα)-positive breast cancer tissues [22]. The
potential binding sites of miR-206 was identified in the
3′UTR of human ERα gene [22, 23], suggesting a mutually
inhibitory feedback loop between ERα and miR-206.
miR-17-5p (also known as miR-91), located on chromo-
some 13q31, seems to exert the role as a tumor suppressor in
breast cancer. Study demonstrated that miR-17-5p regulated
AIB1 (Amplified in Breast Cancer-1 protein) [24]. AIB1 is
a coactivator for nuclear receptors, such as ER. It is overex-
pressed in breast cancer and can promote breast cancer cell
proliferation through an increase in the transactivation of
ER. Study also found that the loss of heterozygosity of miR-
17-5p genomic location occurred in breast cancer. These
findings highlight miR-17-5p act as a tumor suppressor
affecting critical molecular events involved in breast cancer
progression.
Another miRNA as a potential tumor suppressor in
breast cancer is miR-125b or miR-125b. miR-125a and -b
were downregulated in breast cancer [9]. Study demon-
strated that either miR-125a or miR-125b can suppress the
expression of HER2 and HER3 [25]; two important tyrosine
kinase receptors frequently deregulated in breast cancer.
Restoration of miR-125a/b impaired tumor cell growth and
reduced tumor cell migration and invasion, suggesting a
therapeutic use of miRNAs in tumor suppression.
Cancers may arise from rare self-renewing tumor-
initiating cells (T-IC). However, how T-IC self-renewal, mul-
tipotent differentiation, and tumorigenicity are maintained
remains unresolved. By comparing miRNA profiling in self-
renewing and differentiated cells from breast cancer lines and
in breast T-IC (BT-IC) and non-BT-IC from 1 degree breast
cancers, let-7 were found to be markedly reduced in BT-IC
and increased with differentiation [26]. Restoration of let-
7 in BT-IC reduced proliferation, mammosphere formation,
and the proportion of undifferentiated cells in vitro and
tumor formation and metastasis in NOD/SCID mice, while
antagonizing let-7 by antisense oligonucleotides enhanced in
vitro self renewal of non-T-IC. Increased let-7 reduced both
H-RAS and HMGA2, indicating that both genes are let-7
targets. Therefore let-7 regulates multiple BT-IC stem cell-
like properties by silencing more than one target.
Breast cancer metastasis suppressor 1 (BRMS1) is a
predominantly nuclear protein that differentially regulates
expression of multiple genes, leading to suppression of
metastasis without blocking orthotopic tumor growth in
multiple human and murine cancer cells of diverse ori-
gins. Hurst et al. found that BRMS1 suppresses metastasis
via alteration of miR-146 expression and associated with
decreased signaling through the nuclear factor-kappaB path-
way [27]. Furthermore, they showed that BRMS1 signif-
icantly upregulates miR-146a and miR-146b in metastatic
breast cancer cells. Transduction of miR-146a or miR-
146b downregulated expression of epidermal growth factor
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Table 1: List of miRNAs and their target gene involved in human breast cancer.
MicroRNA Targets Aberrant expression and roles References
MiR-21 BCL2, TPM1, PDCD4, PTEN Overexpressed and play oncogenic role [14–17]
MiR-10b Homeobox D10 Down modulated, but associated with metastatic potential [20]
MiR-27a ZBTB10 Oncogenic role in breast cancer cells [21]
MiR-206 ERα Overexpressed [22, 23]
MiR-17-5p AIB1 Oncosuppressor in breast cell lines [24]
MiR-125a, miR-125b ERBB2, ERBB3 Down modulated and act as oncosuppressor [9, 25]
Let-7 RAS, HMGA2 Down modulated and reduced in BT-ICs [26]
MiR-205 HER3 Down modulated [27]
receptor, inhibited invasion, and migration in vitro, and
suppressed experimental lung metastasis. These findings
further support the recent notion that modulating the levels
of miR-146a or miR-146b could have a therapeutic potential
to suppress breast cancer metastasis. A summary of miRNAs
and their target genes associated with breast cancer are listed
in Table 1.
4. miRNAs as Tools for Diagnosis and Prognosis
Since numerous investigations demonstrated that miRNAs
are involved in cancer development and metastasis, miRNAs
are now being explored to have great cancer diagnostic
and prognostic potentials. Emerging evidence revealed that
pattern of miRNAs expression correlated well with clin-
icopathological characteristics and disease outcome. In a
previous study of chronic lymphocytic leukemia, a unique
signature of 13 miRNAs was associated with prognostic
factors and disease progression [28]. Another study reported
that expression signatures of several miRNAs could accu-
rately discriminate acute myeloid leukemia with common
translocation [29]. Furthermore, high expression of miR-155
and low expression of let-7a-2 were associated with poor
prognosis in human lung cancer [30].
In human breast cancer, several studies revealed that
miRNAs act as biomarkers in diagnosis and prognosis [31,
32]. One recent study on 219 early breast cancer patients
identified that expression level of miR-210 was inversely
correlated with disease-free and overall survival, suggesting
that miR-210 could be an independent prognostic factor for
breast cancer [33]. Another study using miRNA microarray
profiling investigated miRNA expression pattern associated
with clinicopathological characteristics and patient survival
and revealed that overexpressed miR-21 was associated with
specific breast cancer pathological features such as advanced
tumor stage, lymph node metastasis, and poor survival [16].
Intriguingly, one recent report identified that miR-7, miR-
128a, miR-210, and miR-516-3p were associated with tumor
aggressiveness in ER positive and lymph node negative and
miR-210 linked with early relapse in ER positive and lymph
node negative breast cancer [13]. Furthermore, low levels
of miR-335 and miR-126 expression were identified to be
strongly correlated with metastatic relapse in breast cancer
patients [34].
Although miRNAs have been identified as biomarkers
either in cancer cell lines or in biopsy specimens, the invasive
nature of a biopsy makes it unsuitable for cancer screening in
high-risk populations. It would be desirable to have amethod
that could accurately detect cancer without resorting to an
invasive procedure. Recently, several reports suggest that cell-
free circulating miRNAs are detectable in serum/plasma and
the levels of tumor-derived miRNAs elevated in the patients
with tongue cancer [35], lung cancer [36], prostate cancer
[37], ovarian cancer [38], and colorectal cancer [39]. These
findings suggest that blood-based miRNAs could emerge
as revolutionary sources of biomarker for breast cancer
diagnosis.
5. Potential Usefulness of miRNA in
Breast Cancer Therapy
As emerging evidences highlight the importance of miRNAs
in diagnosis and prognosis of breast cancer, the usefulness of
miRNA-based breast cancer therapy is now being explored.
MiRNA-based cancer therapy seems to offer an alterna-
tive for targeting multiple gene networks that are controlled
by a single miRNA. In breast cancer, it would be reasonable
to consider miRNAs to be involved in specific networks,
such as the HER family-mediated or ER-driven signaling.
These pathways are likely to be able to alter the response to
chemotherapy or to targeted therapy, such as Trastuzumab
(directed against HER2) or Tamoxifen (antioestrogen). The
previous findings that miR-206 regulated ERα expression in
breast cancer [22] support the suggestion that miR-206 could
be a novel candidate for endocrine therapy to specifically
target ERα. Since miR-125a/b was another miRNA involved
in HER family-mediated pathway [25], such miRNA could
be another target to investigate the mechanism of action of
Trastuzumab to the perturbation of signaling pathway in
cancer cells.
Another study showed that doxorubicin (DOX)-resistant
breast cancer cells exhibited alterations in miRNA profile and
miR-451 was identified to regulate the expression of mul-
tidrug resistance 1 gene [40]. Further investigation showed
that restoring miR-451 into DOX-resistant breast cancer
cells resulted in the increased sensitivity of cells to DOX,
indicating that restoration of such altered miRNA expression
may have important implications for breast cancer therapy.
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Interestingly, a recent study demonstrated that estradiol
(E2) downregulated miR-21 expression and induced miR-21
target genes, such as PDCD4 and PTEN, expression in breast
cancer cells [18]. Considering that miR-21 was overexpressed
in breast cancer and regulated the tumor suppressor PTEN
in breast cancer [18, 19], there would be great interest
to target miR-21 so as to regulate PTEN in breast cancer
because PTEN has been demonstrated as a modulator of
responsiveness to Trastuzumab [41]. Another miRNA which
may involve in the Trastuzumab-mediated effects is p27
which is an important cell cycle regulator [42]. As miR-221
and miR-222 have been showed to regulate p27 in different
types of cancer [43, 44], the investigation on the relationship
between such miRNAs and p27 in breast cancer may provide
potential therapeutic use for improvement of responsiveness
to Trastuzumab.
HER2 overexpression is a hallmark of a subset of
breast cancer aggressiveness, and its activation is strictly
dependent on the transinteraction with other members of
HER family, in particular, the activation of the PI3K/Akt
survival pathway. Interestingly, a recent study showed that
miR-205, downregulated in breast tumors compared with
normal breast tissue, directly targets HER3 receptor and
inhibits the activation of the downstream mediator Akt
[26]. HER3 plays an important role in HER2-mediated
tumorigenesis, and coexpression of both HER2 and HER3
is a poor prognostic factor. In this study Iorio et al. found
that restoration of miR-205 in breast cancer cells increased
the responsiveness to tyrosine kinase inhibitors Gefitinib
and Lapatinib, abrogating the HER3-mediated resistance
and restoring a potent proapoptotic activity. It suggested
miR-205 as a new oncosuppressor in breast cancer and can
improve the responsiveness to specific anticancer therapies.
Although there is no established model between p53
and miRNAs in breast cancer development, recent intriguing
evidence linking p53 and miR-34 family showed that miR-
34a is a direct target of p53 [45, 46]. It would be interesting
to investigate if miR-34a is deregulated in breast cancer
patients carrying wild-type p53. If so, this would be one of
the mechanisms used by tumor cells to escape the apoptotic
control by p53 and to survive under oncogenic circumstance.
Thus, miRNA-based therapy by restoring miR-34a function
in breast cancer could also be a strategy to improve
responsiveness to chemotherapy.
Apart from chemotherapy, miRNAs have been suggested
to contribute to responsiveness to radiotherapy. In a recent
study, it showed that the let-7 family of miRNAs can suppress
the resistance to radiotherapy in lung cancer cells [47].
These findings are the first direct evidence that miRNAs
can suppress resistance to anticancer cytotoxic therapy, a
common feature of cancer cells, and suggest that miRNAs
may be a viable tool to augment current cancer therapies.
6. Concluding Remarks
The past decades have seen advances in the diagnosis and
treatment of breast cancer. However, breast cancer is still a
leading cause of cancer-related deaths among women, with as
many as 40% relapsing with metastatic disease [48]. Despite
the dedication of research and resources to the elucidation
of molecular mechanisms involved, unpredictable response
and development of resistance to adjuvant therapy remain
major challenges in breast cancer management. The emer-
gence of microRNAs (miRNAs) as upstream regulators of
gene expression is identified as novel candidate diagnostic,
prognostic indicators, and therapeutic targets. Due to the
advancement of high-throughput miRNA expression profil-
ing, the important involvement of miRNAs in breast cancer
development and metastasis has been uncovered. Besides,
miRNAs as biomarkers used for breast cancer diagnosis and
prognosis in clinical setting have important advantages in
contrast to mRNAs: (i) unlike screening for large number
of mRNA expression, a modest number of miRNAs may
be sufficient to differentiate cancers from normal; and (ii)
unlike mRNAs, miRNAs in plasma remain largely intact
and have been proven to be more stable for detection in
paraffin-embedded tissues [49] and even presented in a
remarkably stable form in plasma and serum samples that
is protected from endogenous RNase activity [37]. A recent
study also shows that an added exogenous miRNA (miR-
141) has a slower rate of reduction and remained detectable
for longer periods than placental mRNA, suggesting that
miRNAs have higher stability than mRNAs even in the
absence of any protection (e.g., through association with
particles) from nuclease activity in the plasma [50]. Thus,
with increasing knowledge about miRNAs associated with
molecular subtypes and clinicopathological characteristics of
breast cancer we believe that miRNAs may prove useful as
diagnostic and prognostic tools in the future.
As the therapeutic implications of miRNAs are emerging,
miRNA-based therapeutic strategies can be formulated by
either antagonizing or restoring the functions of miRNAs.
Antisense oligonucleotide technology is already being devel-
oped by using the intrinsic RNA interference (RNAi) path-
way for gene therapy. Specific designed miRNA inhibitors or
synthetic miRNAs targeting genes involved in breast cancer,
such as HER2 [25] has shown some promise of miRNA-
based cancer therapy being used as a powerful tool for
breast cancer therapy. Although it is promising, two major
obstacles must be overcome before it can become a broadly
applicable standard therapy: the question of their specificity
and efficient delivery to the target cells. RNAi applications
are based on base pairing between an oligonucleotide and an
RNA. In practice, a single mismatch can lead to a complete
loss of silencing [51] and so “off-target effects” compromise
the specificity of RNAi if sequence identity between small
interfering RNA (siRNA) and random mRNA transcripts
causes RNAi to knock down expression of nontargeted
genes. If multiple siRNAs are used for targeting multiple
hits, multiple off-target effects will happen. Thus, RNAi
application will never be completely specific. More recent
investigations have shown that by suitable design of the
siRNAs as well as the use of modified nucleotides, however,
the unspecific effects can beminimized [52–55]. The delivery
of miRNA inhibitors or synthetic miRNAs into cells is
one of the greatest challenges to the development of this
application. Despite the advances of the past few years,
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further developments are still required to get systemically
applied miRNA inhibitors to their required site of action.
Although viral vector systems offer additional options for
efficient and organ-specific delivery, this approach must first
overcome the reservations based on the negative experience
with gene therapy.
The specific inhibition of a single target gene is usually
attempted, and experience in the antisense field has shown
that this can, under some circumstances, be insufficient for
complex diseases such as cancer. In contrast, miRNAs affect
many target RNAs, so that more comprehensive regulation
can be achieved with the inhibition of a single miRNA. Thus,
further understanding of the functional roles of miRNAs
will open up new opportunities in developing revolutionary
therapeutic strategies for breast cancer chemoprevention.
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